NCT01867190View on ClinicalTrials.gov

Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Critical Limb Ischemia
Interventions
BIOLOGICAL

ASCT01 (Autologous Stem Cell Transplantation)

Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route

Trial Locations (1)

64116

Kansas City Vascular Foundation (KCV), North Kansas City

All Listed Sponsors
lead

Lifecells, LLC.

INDUSTRY

NCT01867190 - Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia | Biotech Hunter | Biotech Hunter